Clenpiq received FDA approval on July 24, 2023 [1]. The drug is a sodium phosphate solution indicated for cleansing the colon in preparation for colonoscopy in adults [1].
What is Clenpiq's active ingredient and how does it work?
Clenpiq is a dual-acting laxative containing sodium phosphate and magnesium citrate [1]. It works by drawing water into the colon, which softens the stool and stimulates bowel movements to clear the colon [1].
What are the potential side effects of Clenpiq?
Common side effects of Clenpiq can include nausea, vomiting, headache, and abdominal distention [1]. Patients with certain pre-existing conditions, such as kidney disease, may be at a higher risk for adverse events, including serious kidney problems [1]. It is important for patients to discuss their medical history with their healthcare provider before using Clenpiq [1].
How does Clenpiq compare to other colonoscopy preparation methods?
Clenpiq is one of several options available for colonoscopy preparation. Other methods include polyethylene glycol-based solutions, stimulant laxatives, and magnesium citrate [1]. The choice of preparation often depends on individual patient factors, physician preference, and tolerability [1].
When does Clenpiq's patent protection end?
Information regarding the specific patent expiration dates for Clenpiq is not publicly available in the provided information. Drug patent data can be tracked on resources like DrugPatentWatch.com [2].
Who is the manufacturer of Clenpiq?
Clenpiq is manufactured by Ferring Pharmaceuticals [1].
What are the FDA's recommendations for using Clenpiq?
The FDA approval signifies that Clenpiq has met the agency's standards for safety and effectiveness for its intended use. Patients are advised to follow the specific dosing instructions provided by their healthcare provider and on the product labeling to ensure optimal colon cleansing and minimize risks [1].
Are there any contraindications for using Clenpiq?
Clenpiq is contraindicated in patients with congestive heart failure, ascites, gastric retention, gastrointestinal obstruction, toxic megacolon, ileus, or known or suspected perforation of the gastrointestinal tract, or in patients who are unable to retain the recommended dose prior to their procedure [1]. It is also not recommended for patients with severe renal impairment [1].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases-aceut-2023
[2] https://drugpatentwatch.com/